Welcome to our dedicated page for Appili Ther news (Ticker: APLIF), a resource for investors and traders seeking the latest updates and insights on Appili Ther stock.
Appili Therapeutics Inc. develops anti-infective products for infectious diseases and biodefense. Company updates cover its portfolio of LIKMEZ (ATI-1501), an FDA-approved ready-made metronidazole suspension; ATI-1701, a live-attenuated tularemia vaccine candidate; ATI-1801, a topical antiparasitic program for cutaneous leishmaniasis; and collaborations involving VXV-01, a fungal vaccine program.
Recurring news also addresses non-dilutive government funding, NIAID and U.S. Air Force Academy-supported development work, manufacturing and regulatory activities, financial and operational results, scientific and biodefense conference participation, and shareholder meeting outcomes.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) released its financial results for Q3 of FY2021, reporting a net loss of $9.34 million, up from $4.13 million in the same period the previous year. Key operational highlights include a collaboration with Dr. Reddy’s Laboratories to advance the COVID-19 antiviral favipiravir, and the initiation of clinical trials for its PRESECO study. As of December 31, 2020, the company had cash and short-term investments of $20.29 million. Appili remains committed to addressing COVID-19 through its antiviral programs.
Appili Therapeutics has appointed Rochelle Stenzler to its Board of Directors. Stenzler is a seasoned executive with a wealth of experience in healthcare, previously leading companies like TouchLogic Corporation and Revlon Canada. Her expertise in governance and leadership aims to support Appili during a critical phase in its development of favipiravir and other anti-infective programs. Stenzler's background includes significant roles in corporate governance, enhancing the board's capability to drive the company's mission against infectious diseases.
Appili Therapeutics (TSX: APLI, OTCQX: APLIF) announced the recruitment for its Phase 3 PRESECO trial, evaluating favipiravir for early COVID-19 treatment. The trial is currently enrolling participants at 12 of 20 planned sites in the U.S., aiming for an interim data readout by March 2021. Appili is also seeking regulatory approvals to expand the trial into Mexico, Brazil, and Colombia. Favipiravir, an oral antiviral, has shown significant potential in treating mild to moderate COVID-19, and Appili is focusing resources on accelerating recruitment and data analysis.
Appili Therapeutics (TSX: APLI, OTCQX: APLIF) announced that CEO Dr. Armand Balboni will present at HC Wainwright’s inaugural BioConnect 2021 virtual conference from January 11-14, 2021. The pre-recorded presentation will be available on demand starting January 11 at 6:00 AM ET for one week. This conference serves as a forum for companies to connect with investors during the JP Morgan Healthcare Conference. Appili focuses on developing novel therapies for life-threatening infections, including advancing clinical trials for the antiviral Avigan® for COVID-19 treatment.